A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Status:
Unknown status
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the non-inferiority of overall survival
FOLFIRI with or without Bevacizumab compared with Irinotecan (CPT-11) with or without
Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.